Back to top
more

Ultragenyx Pharmaceutical (RARE)

(Delayed Data from NSDQ)

$44.86 USD

44.86
604,658

-0.20 (-0.44%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $44.83 -0.03 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

What's in Store for Zoetis (ZTS) Stock This Earnings Season?

Zoetis Inc. (ZTS) is scheduled to report first-quarter 2017 results on May 4.

    What to Expect from Endocyte (ECYT) Stock for Q1 Earnings?

    Endocyte, Inc (ECYT) is expected to report first-quarter 2017 results on May 3.

      What's in Store for Juno Therapeutics (JUNO) in Q1 Earnings?

      Juno Therapeutics Inc. (JUNO) is scheduled to report first-quarter 2017 results on May 4, after the market closes.

        What to Expect from Keryx (KERX) Stock This Earnings Season?

        Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2017 results on May 4.

          BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?

          We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.

            What's in Store for Nivalis (NVLS) this Earnings Season?

            Nivalis Therapeutics, Inc. (NVLS) is expected to report first-quarter 2017 results early next month. Last quarter, the company had a positive surprise of 9.09%.

              What's in Store for Vertex (VRTX) this Earnings Season?

              Vertex Pharmaceuticals, Inc. (VRTX) is scheduled to report first-quarter 2017 results on Apr 27, after the market closes.

                What's in Store for AbbVie (ABBV) this Earnings Season?

                AbbVie Inc. (ABBV) is slated to release first-quarter 2017 earnings, before the opening bell on Apr 27.

                  Company News for April 20, 2017

                  Companies in the News are: LRCX,FB,RARE,ABT

                    Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III

                    Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH).

                      Ultragenyx's (RARE) XLH Drug Positive in Phase II Study

                      Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Kirin International plc recently announced positive 64-week data from a pediatric phase II study, evaluating its investigational candidate burosumab (KRN23).

                        Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study

                        Ultragenyx Pharmaceutical Inc. (RARE) recently announced that its pipeline candidate UX007 (triheptanoin) failed to meet the primary endpoint in a phase II study evaluating it for the treatment of patients with Glut1 DS with seizures.

                          Ultragenyx's (RARE) KRN23 Accepted for Review in the EU

                          Ultragenyx (RARE) announced that EMA has accepted to review its MAA for KRN23 for the treatment of X-linked hypophosphatemia.

                            Ultragenyx (RARE) Reports Positive Phase II Study on UX007

                            Ultragenyx (RARE) announced positive data from a phase II study on UX007 for the treatment of patients with long-chain fatty acid oxidation disorder (LC-FAOD).